In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...
Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...
The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...
The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...
During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, discussed 2 recent trials in multiple myeloma for ...
The Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) with Velcade (bortezomib), Revlimid ...
Sanofi has claimed FDA approval for its anti-CD38 drug isatuximab as a third-line treatment for multiple myeloma, becoming the first direct rival to Johnson & Johnson’s big-selling Darzalex.
The Company’s pipeline of therapeutic candidates with standard-of-care agents include: About SARCLISASARCLISA (isatuximab-irfc) is a monoclonal antibody that binds to a specific epitope on the ...
Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal ...
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981 Technology appraisal guidance TBC Isatuximab with pomalidomide and dexamethasone for treating ...
Now, the group's only mid- to late-stage cancer programmes include efforts to extend the indications of blood cancer therapy Sarclisa (isatuximab) and phase 2 anti-ICOS antibody alomfilimab for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback